Trump announces trade deal with EU following months of negotiations
DAIX, FRANCE/NEW YORK - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company with a market capitalization of $472 million focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), announced Tuesday the appointment of Renée Aguiar-Lucander to its Board of Directors. The company’s stock has surged nearly 40% over the past six months, according to InvestingPro data.
The appointment, approved by shareholders at the company’s recent Annual General Meeting, comes as Inventiva advances its lead drug candidate lanifibranor through late-stage clinical development.
Aguiar-Lucander currently serves as Chief Executive Officer of Hansa Biopharma, a position she has held since April 2025. She previously led Calliditas Therapeutics, where she oversaw the company’s transformation from a small biotech to a commercial-stage enterprise that achieved the first FDA approval for a treatment in IgA nephropathy. Her tenure at Calliditas culminated in its $1.1 billion acquisition by Asahi Kasei in 2024.
"With the NATiV3 Phase 3 trial fully enrolled, I look forward to working with the team to potentially bring lanifibranor to patients with MASH," said Aguiar-Lucander in the press release statement. While the company maintains impressive gross profit margins of 90%, InvestingPro analysis shows it’s currently burning through cash with an EBITDA of -$97 million in the last twelve months.
Prior to her role at Calliditas, Aguiar-Lucander held senior positions in life sciences investment and corporate finance, including Partner and COO at Omega Fund Management and Managing Director at a global investment bank. She holds an MBA from INSEAD and a BA in Finance from the Stockholm School of Economics.
Inventiva is currently evaluating lanifibranor, a pan-PPAR agonist, in the pivotal NATiV3 Phase 3 clinical trial for the treatment of adult MASH patients. Analysts maintain a bullish outlook on the company, with InvestingPro showing 6 additional key insights about Inventiva’s financial health and market position. Get full access to these insights and more with an InvestingPro subscription.
In other recent news, Inventiva SA has announced the terms of its share repurchase program, approved at its Ordinary General Meeting. The program will last for 18 months, allowing the company to buy back up to 10% of its issued share capital, with a maximum purchase price set at 40 euros per share. This initiative aims to enhance liquidity and support employee stock option programs. Meanwhile, Inventiva has completed patient enrollment for its Phase 3 NATiV3 trial, a significant step toward the anticipated topline results in the latter half of 2026. The trial exceeded its initial targets, enrolling 1,009 patients in the main cohort and 410 in the exploratory cohort. Guggenheim Securities has adjusted its price target for Inventiva from $12.00 to $9.00 but maintains a Buy rating, citing the company’s progress and potential of its lead treatment, lanifibranor. Stifel analysts also reiterated their Buy rating with a $17.00 price target, highlighting positive safety reviews and potential for the NATiV3 trial to replicate previous successful results. The completion of the trial’s enrollment satisfies conditions for a second tranche of €116 million in structured financing, crucial for the company’s financial strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.